This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutInfliximabWhat is infliximabInflammatory Bowel DiseaseMaximising patient outcomes with IBDBiosimilarsWhat is a biosimilarFuture of biosimilarsBiologic switchingINFLECTRA® Introducing INFLECTRA® Position statementsECCOEULARESPGHANDosing & safetyDosingIV dosingAdministration & storageAdministrationStorageSafety informationImportant safety informationConsiderations for SwitchingSwitching to InflectraSafety informationImportant safety informationSafety informationSafety informationClinical evidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceReal-world experienceSummary: real-world evidenceSupporting ResourcesVideosMaterialsPatient Support


Inflectra®(infliximab) Prescribing Information. Adverse events reporting information can be found at the bottom of the page.

 


INFLECTRA® (CT-P13*/infliximab) was first infliximab infusion licensed in the EU1
  • More than 7 years of clinical experience1
     
  • Approved in more than 80 countries2
     
  • Approved across all of the same populations as Remicade™,‡ including 2 paediatric populations3,4
     
    • In gastroenterology: Crohn’s disease, ulcerative colitis, paediatric Crohn’s disease and paediatric ulcerative colitis
       
    • In rheumatology: rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
       
    • In dermatology: psoriasis
 INFLECTRA®

INFLECTRA® was first approved biosimilar of infliximab infusion therapy1

 Evidence

INFLECTRA® infusion therapy has been evaluated across a range of studies5-8

 Resources

Pfizer provides a wealth of resources to support both patients and healthcare providers

CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.INFLECTRA® (CT-P13/infliximab) infusion therapy has demonstrated comparable efficacy and safety to Remicade™ (infliximab) in rigorous clinical studies for RA and AS and, via extrapolation, has been granted a European Commission licence for all of the same clinical indications as Remicade™.1,3,9 Guidelines state that “Extrapolation of clinical efficacy and safety data to other indications of the reference mAb, not specifically studied during the clinical development of the biosimilar mAb, is possible based on the results of the overall evidence provided from the comparability exercise and with adequate justification.”1,9Remicade™ is a registered trademark of MSD.AS, Ankylosing spondylitis; mAb, Monoclonal antibody; RA, Rheumatoid arthritis.References:European Public Assessment Report: INFLECTRA®. 27 June 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/human/002778/ WC500151490.pdf. Accessed February 2021.Yoo DH. Expert Rev Clin Immunol 2017;13(7):653-66.INFLECTRA® Summary of Product Characteristics.Remicade™ Summary of Product Characteristics.Byong Duk Y, et al. Lancet 2019;393:1699-707.Strik AS, et al. Lancet Gastroenterol Hepatol 2018;3:404-12.Armuzzi A, et al. Inflamm Bowel Dis 2019;25:568-79.Hlavaty T, et al. Gastroenterol Hepatol 2016;70:27-36.Guidelines on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 30 May 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2012/06/WC500128686.pdf. Accessed February 2021.
PP-IFA-GBR-0605. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​